ERYtech Pharma Receives € 7 Million from OSEO to Lead the TEDAC Personalized Medicine Project in Cancer

LYON, France & PHILADELPHIA--(BUSINESS WIRE)--ERYTECH Pharma, a late-stage French biopharmaceutical company developing medicinal products for oncology, is pleased to announce that it received a total of € 6.95 million in support from the Strategic Industrial Innovation program of the French public organization OSEO to lead the TEDAC project (Therapeutic Enzymes to Deplete Amino acids to treat Cancers resistant to radio/chemotherapy).